Reshape Lifesciences Inc. Stock Price, News & Analysis

ReShape Lifesciences (NASDAQ:RSLS) announced strategic cost reductions and updates on pending transactions. The company is implementing a workforce reduction expected to save over $750,000 annually, representing 23.4% of payroll expenses, while maintaining its sales and marketing team intact.

The company is progressing with its merger agreement with Vyome Therapeutics and an asset purchase agreement with Biorad Medisys. A special shareholder meeting is scheduled for July 24, 2025 to vote on these strategic transactions. The Board of Directors has unanimously endorsed these deals, viewing them as transformative opportunities for long-term value creation.

ReShape Lifesciences (Nasdaq: RSLS) has secured a significant Australian patent for its Diabetes Neuromodulation technology, valid until April 2039. The technology utilizes the company's proprietary vBloc™ platform to treat Type 2 diabetes through vagus nerve modulation.

The system employs targeted bioelectronic modulation of vagal nerves using implanted electrodes and an intelligent pulse generator that interfaces with external devices and glucose monitors. Preclinical studies in Zucker rats and alloxan-treated swine have demonstrated effective glycemic control. The technology is supported by 63 issued or pending patents covering areas including vagal neuromodulation, glucose regulation, artificial intelligence, and Bluetooth-enabled applications.

ReShape Lifesciences (RSLS) has signed an exclusive U.S. distribution agreement with Recon Supply to distribute its product portfolio across VA and DoD healthcare systems. The agreement covers ReShape's STIMEL-03 neuromuscular rehabilitation device and Lap-Band® 2.0 FLEX weight loss solution, targeting over 18 million veterans and active military personnel. Recon Supply, which has grown 113% year-over-year since 2022, currently distributes to 102 VA Medical Centers through various federal contracts including DAPA, FSS, and ECAT. The partnership aims to expand access to ReShape's FDA-cleared medical technologies for veterans and military personnel recovering from stroke, injury, surgery, or struggling with obesity.

ReShape Lifesciences (NASDAQ: RSLS), a physician-led weight loss and metabolic health solutions company, has announced the pricing of a public offering of 1,054,604 common stock shares at $2.50 per share. The offering is expected to generate gross proceeds of approximately $2.6 million before deducting placement agent fees and other expenses. The offering, set to close around June 9, 2025, is being conducted through Maxim Group LLC as the sole placement agent. The offering is made possible through an effective shelf registration statement on Form S-3 filed with the SEC on May 9, 2025, and declared effective on May 14, 2025.

ReShape Lifesciences (RSLS) has achieved EU Medical Device Regulation (MDR) certification and UK Conformity Assessment (UKCA) certification for its entire product portfolio and Quality Management System ahead of the December 31, 2027 deadline. This certification ensures compliance with stringent European and UK regulatory requirements for medical devices, covering clinical evaluation, post-market surveillance, and device traceability across all 30 European Economic Area countries. The achievement positions ReShape among a select group of medical device manufacturers meeting these new standards, ensuring uninterrupted product availability in European markets and supporting future innovation in obesity treatment solutions.

ReShape Lifesciences (RSLS) reported Q1 2025 financial results and provided corporate updates. The company reported revenue of $1.1 million, down 42.7% year-over-year, primarily due to GLP-1 pharmaceutical competition. Key developments include: a 1-for-25 reverse stock split effective May 9, 2025; completion of a $6.0 million public offering; and progress on the pending merger with Vyome Therapeutics and asset sale to Biorad Medisys. The company secured multiple patent allowances for its Diabetes Neuromodulation technology and signed distribution agreements with Motion Informatics and Liaison Medical. Financial metrics show gross profit at $0.7 million with a 61.2% margin, and cash position of $2.6 million as of March 31, 2025.

ReShape Lifesciences (NASDAQ: RSLS) has announced a 1-for-25 reverse stock split of its common stock, effective for trading on May 9, 2025. Following the split, every 25 shares of outstanding common stock will be consolidated into one share. The company will make proportional adjustments to outstanding warrants, stock options, and convertible preferred stock. Any fractional shares will be rounded up to the nearest whole share.

The reverse split was approved by stockholders on April 1, 2025. The company's transfer agent, Equiniti Trust Company, will provide instructions for exchanging existing certificates. The new CUSIP number will be 76090R408. The number of authorized shares under the company's certificate of incorporation will remain unchanged.

ReShape Lifesciences (RSLS) presented pre-clinical data on its Diabetes Neuromodulation device at the Minnesota Neuromodulation Symposium. The device uses Hypoglycemia Vagus Nerve Stimulation (HVNS) to target the sub-diaphragmatic posterior vagus nerve, effectively increasing blood glucose during hypoglycemic episodes without cardiac side effects. In the Type 1 diabetic swine model study, HVNS successfully elevated glucose levels from 45 to 58 mg/dL and 51 to 68 mg/dL in two subjects after 30 minutes, while increasing glucagon levels. The technology demonstrated a clear therapeutic window, with side effects only occurring at current amplitudes above therapeutic levels. This innovation could potentially reduce dependence on injections and wearable glucose monitors for Type 1 and Type 2 diabetes patients.

ReShape Lifesciences (Nasdaq: RSLS) has received a Notice of Allowance from the USPTO for patent application 18/241,151, titled 'Intragastric Device.' The patent covers an innovative intragastric balloon system featuring a swallowable capsule with self-sealing fill valve and degradable release valve.

The system is designed to deflate approximately three months after saline inflation and is configured for natural excretion. The patent will provide protection until at least January 2031, with potential for extension.

Since their initial filing in 2011, the company has secured over 50 patents related to their intragastric balloon system. ReShape currently maintains a portfolio of more than 160 patents issued and pending across various protected technologies.